pde2a in 1

PDE2A-IN-1 is a phosphodiesterase 2A (PDE2A) inhibitor with an IC50 value of 1.3 nM.

CP 461 (UNII-68OJX9I7DT), a specific PDE2A inhibitor, is a novel pro-apoptotic compound that inhibits cyclic GMP phosphodiesterase but not cyclooxygenase-1 or -2. CP 461 inhibits the growth of a variety of human tumor cell lines in vitro and selectively induces apoptosis in cancer cell lines, but not in normal cells.

PDE2 inhibitor6 (Compound 1) is an orally active phosphodiesterase (PDE) inhibitor, effectively inhibiting PDE2A, PDE3B, and PDE10A2 with IC50 values of 0.95 nM, 6.17 μM (pIC50=5.21), and 87.1 nM (pIC50=7.06), respectively. It modulates AMPA receptor activity, enhances synaptic plasticity, and improves learning and memory in rat models. Furthermore, PDE2 inhibitor6 possesses blood-brain barrier permeability.

Hcyb1 is a potent and specific inhibitor of phosphodiesterase 2 (PDE2). It exhibits a high degree of selectivity for inhibiting PDE2A with an IC50 value of 0.57 μM. In addition, Hcyb1 displays over 250-fold selectivity against other recombinant members of the PDE family. Moreover, its pharmacological actions include neuroprotective and antidepressant-like effects, which are believed to be mediated through the cAMP/cGMP-CREB-BDNF signaling pathway [1].